Key points are not available for this paper at this time.
and carbapenem-resistant Enterobacteriaceae. Taniborbactam is the first pan-spectrum β-lactamase inhibitor to enter clinical development.
Share your take
Add a clinician perspective alongside expert commentary.
Liu et al. (Mon,) studied this question.